The Experts below are selected from a list of 23154 Experts worldwide ranked by ideXlab platform
Henry Krum - One of the best experts on this subject based on the ideXlab platform.
-
systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease
American Journal of Cardiovascular Drugs, 2001Co-Authors: Sheila M Killalea, Henry KrumAbstract:Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy in the management of angina pectoris. However, hepatic and neurological adverse effects associated with perhexiline administration led to a marked decline in its use. The drug was originally classified as a coronary vasodilator, and later as a calcium channel antagonist, but recent data suggests that it acts as a cardiac Metabolic Agent, through inhibition of the enzyme, carnitine palmitoyltransferase-1 (CPT-1).
Sheila M Killalea - One of the best experts on this subject based on the ideXlab platform.
-
systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease
American Journal of Cardiovascular Drugs, 2001Co-Authors: Sheila M Killalea, Henry KrumAbstract:Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy in the management of angina pectoris. However, hepatic and neurological adverse effects associated with perhexiline administration led to a marked decline in its use. The drug was originally classified as a coronary vasodilator, and later as a calcium channel antagonist, but recent data suggests that it acts as a cardiac Metabolic Agent, through inhibition of the enzyme, carnitine palmitoyltransferase-1 (CPT-1).
Benedetta C Sallustio - One of the best experts on this subject based on the ideXlab platform.
-
comparison of cyp2d metabolism and hepatotoxicity of the myocardial Metabolic Agent perhexiline in sprague dawley and dark agouti rats
Xenobiotica, 2015Co-Authors: Giovanni Licari, Andrew A. Somogyi, Robert W. Milne, Benedetta C SallustioAbstract:Abstract1. Perhexiline, a chiral anti-anginal Agent, may be useful to develop new cardiovascular therapies, despite its potential hepatotoxicity.2. This study compared Dark Agouti (DA) and Sprague–Dawley (SD) rats, as models of perhexiline’s metabolism and hepatotoxicity in humans. Rats (n = 4/group) received vehicle or 200 mg/kg/d of racemic perhexiline maleate for 8 weeks. Plasma and liver samples were collected to determine concentrations of perhexiline and its metabolites, hepatic function and histology.3. Median (range) plasma and liver perhexiline concentrations in SD rats were 0.09 (0.04–0.13) mg/L and 5.42 (0.92–8.22) ng/mg, respectively. In comparison, DA rats showed higher (p < 0.05) plasma 0.50 (0.16–1.13) mg/L and liver 24.5 (9.40–54.7) ng/mg perhexiline concentrations, respectively, 2.5- and 3.7-fold higher cis-OH-perhexiline concentrations, respectively (p < 0.05), and lower plasma Metabolic ratio (0.89 versus 1.55, p < 0.05). In both strains, the (+):(−) enantiomer ratio was 2:1. Perhexilin...
Giovanni Licari - One of the best experts on this subject based on the ideXlab platform.
-
comparison of cyp2d metabolism and hepatotoxicity of the myocardial Metabolic Agent perhexiline in sprague dawley and dark agouti rats
Xenobiotica, 2015Co-Authors: Giovanni Licari, Andrew A. Somogyi, Robert W. Milne, Benedetta C SallustioAbstract:Abstract1. Perhexiline, a chiral anti-anginal Agent, may be useful to develop new cardiovascular therapies, despite its potential hepatotoxicity.2. This study compared Dark Agouti (DA) and Sprague–Dawley (SD) rats, as models of perhexiline’s metabolism and hepatotoxicity in humans. Rats (n = 4/group) received vehicle or 200 mg/kg/d of racemic perhexiline maleate for 8 weeks. Plasma and liver samples were collected to determine concentrations of perhexiline and its metabolites, hepatic function and histology.3. Median (range) plasma and liver perhexiline concentrations in SD rats were 0.09 (0.04–0.13) mg/L and 5.42 (0.92–8.22) ng/mg, respectively. In comparison, DA rats showed higher (p < 0.05) plasma 0.50 (0.16–1.13) mg/L and liver 24.5 (9.40–54.7) ng/mg perhexiline concentrations, respectively, 2.5- and 3.7-fold higher cis-OH-perhexiline concentrations, respectively (p < 0.05), and lower plasma Metabolic ratio (0.89 versus 1.55, p < 0.05). In both strains, the (+):(−) enantiomer ratio was 2:1. Perhexilin...
Andrew A. Somogyi - One of the best experts on this subject based on the ideXlab platform.
-
comparison of cyp2d metabolism and hepatotoxicity of the myocardial Metabolic Agent perhexiline in sprague dawley and dark agouti rats
Xenobiotica, 2015Co-Authors: Giovanni Licari, Andrew A. Somogyi, Robert W. Milne, Benedetta C SallustioAbstract:Abstract1. Perhexiline, a chiral anti-anginal Agent, may be useful to develop new cardiovascular therapies, despite its potential hepatotoxicity.2. This study compared Dark Agouti (DA) and Sprague–Dawley (SD) rats, as models of perhexiline’s metabolism and hepatotoxicity in humans. Rats (n = 4/group) received vehicle or 200 mg/kg/d of racemic perhexiline maleate for 8 weeks. Plasma and liver samples were collected to determine concentrations of perhexiline and its metabolites, hepatic function and histology.3. Median (range) plasma and liver perhexiline concentrations in SD rats were 0.09 (0.04–0.13) mg/L and 5.42 (0.92–8.22) ng/mg, respectively. In comparison, DA rats showed higher (p < 0.05) plasma 0.50 (0.16–1.13) mg/L and liver 24.5 (9.40–54.7) ng/mg perhexiline concentrations, respectively, 2.5- and 3.7-fold higher cis-OH-perhexiline concentrations, respectively (p < 0.05), and lower plasma Metabolic ratio (0.89 versus 1.55, p < 0.05). In both strains, the (+):(−) enantiomer ratio was 2:1. Perhexilin...